Computer'Nudge' Spurs Doctors to Prescribe Statins to Heart Patients

FRIDAY, Oct. 9, 2020 -- Prescriptions of cholesterol-lowering statins for heart disease patients rose significantly when doctors were prompted to choose whether or not to order them, according to a new study. It included 82 cardiologists and more...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Cardiovascular diseases (CVDs) are the main cause of mortality worldwide. Risk factors of CVD can be classified into modifiable (smoking, hypertension, diabetes, hypercholesterolemia) through lifestyle changes or taking drug therapy and not modifiable (age, ethnicity, sex and family history). Elevated total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) levels have a lead role in the development of coronary heart disease (CHD), while high levels of high-density lipoprotein-cholesterol (HDL-C) seem to have a protective role. The current treatment for dyslipidemia consists of lifestyle modification or drug...
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Review Source Type: research
Conditions:   Rheumatic Heart Disease;   Valvular Disease Interventions:   Drug: Atorvastatin;   Drug: Placebo Sponsors:   University of Washington;   Manmohan Cardiothoracic Vascular and Transplant Center;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
By KEN TERRY (This is the eighth and final installment in a series of excerpts from Terry’s new book, Physician-Led Healthcare Reform: a New Approach to Medicare for All, published by the American Association for Physician Leadership.) Medical technologies include drugs, devices, tests, and procedures. Considered as a whole, these technologies are the key driver of growth in health costs, according to Georgetown University professor Gregg Bloche and his associates. Bloche, et al., view insurance coverage as the chief enabler of these technological innovations. In a 2017 Health Affairs Blog post, they sai...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Ken Terry Source Type: blogs
Conditions:   Rheumatic Heart Disease;   Valvular Disease Interventions:   Drug: Atorvastatin;   Drug: Placebo Sponsors:   University of Washington;   Manmohan Cardiothoracic Vascular and Transplant Center;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractPurpose of ReviewHypertriglyceridaemia is a highly prevalent disorder worldwide. Genetic and Mendelian randomization studies have suggested that triglyceride (TG)-rich lipoproteins are causal risk factors for coronary heart disease and contribute to the residual cardiovascular risk observed in patients optimally treated with statins. However, clinical trials failed to show cardiovascular benefits of TG-lowering; in this context, trials with omega-3 fatty acids provided contrasting results. Few trials have tested the supplementation of EPA alone rather than the combination of EPA + DHA. The JELIS study showed that E...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
Managing modifiable risk factors, such as cholesterol and blood pressure, is the conventional strategy to combat heart disease, the number 1 cause of death in the United States. Medications for lowering cholesterol and blood pressure have also been shown to play a role in bone metabolism. As such, these medications are of potential interest to the osseointegration and health of dental implants. Given the widespread use of these medications, it is imperative to understand their role in enhancing or deteriorating the health of dental implants.
Source: Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Source Type: research
ConclusionCardiovascular morbidity was increased in patients with TA attending primary care services in the UK. Treatment with statins and anti ‐platelets in these patients was suboptimal.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
This study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture. Ruptured plaque can lead to a heart attack or stroke. The analysis involved 209 middle-aged patients (ages 37-62) with psoriasis who participated in the Psoriasis Atherosclerosis Cardiometabolic Initiative at the National Institutes of Health, an ongoing observational study. Of these participants, 124 received biologic therapy, and 85 were in the control group, treated only with topical creams and light therapy. To measure the effects of biologic ther...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
(Natural News) Heart disease is one of the major causes of death worldwide. It puts a person at risk of heart attack and stroke, which can leave survivors disabled for the rest of their lives. There are drugs used to treat heart disease, such as statins. But these medications often come with side effects and are...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
CONCLUSIONS: Multimorbid patients with ACS are at a greater risk for worse outcomes than their nonmultimorbid counterparts. Lack of consistent measurement makes interpretation of the impact of multimorbidity challenging and emphasizes the need for more research on multimorbidity's effects on postdischarge healthcare utilization. PMID: 32925234 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Nursing - Category: Nursing Authors: Tags: J Cardiovasc Nurs Source Type: research
More News: Cardiology | Cholesterol | Computers | General Medicine | Heart | Heart Disease | Statin Therapy | Study